BAY-85-8501 is primarily investigated for its potential therapeutic applications in treating respiratory diseases, particularly those involving inflammation and mucus hypersecretion. It is being studied as a selective inhibitor of a specific enzyme involved in the regulation of inflammatory processes, making it a promising candidate for managing conditions like chronic obstructive pulmonary disease (COPD) and asthma. By targeting the underlying mechanisms of inflammation, it aims to reduce symptoms and improve lung function in patients. Research is ongoing to evaluate its efficacy, safety, and potential as a novel treatment option in clinical settings.